Mycophenolate Mofetil Attenuates DOCA-Salt Hypertension: Effects on Vascular Tone

被引:13
|
作者
Moes, Arthur D. [1 ]
Severs, David [1 ]
Verdonk, Koen [2 ]
van der Lubbe, Nils [1 ]
Zietse, Robert [1 ]
Danser, A. H. J. [2 ]
Hoorn, Ewout J. [1 ]
机构
[1] Erasmus Univ, Erasmus Med Ctr, Dept Internal Med, Div Nephrol & Transplantat, Rotterdam, Netherlands
[2] Erasmus Univ, Erasmus Med Ctr, Dept Internal Med, Div Pharmacol & Vasc Med, Rotterdam, Netherlands
来源
FRONTIERS IN PHYSIOLOGY | 2018年 / 9卷
关键词
angiotensin II; endothelin-1; salt-sensitive hypertension; sodium transporters; wire myographs; II TYPE-2 RECEPTOR; SODIUM-CHLORIDE COTRANSPORTER; IMMUNE CELL INFILTRATION; NA-CL COTRANSPORTER; ANGIOTENSIN-II; BLOOD-PRESSURE; SENSITIVE HYPERTENSION; MEDIATED VASODILATION; ACTIVATION; VASOCONSTRICTION;
D O I
10.3389/fphys.2018.00578
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Inflammation is increasingly recognized as a driver of hypertension. Both genetic and pharmacological inhibition of B and T cells attenuates most forms of experimental hypertension. Accordingly, the immunosuppressive drug mycophenolate mofetil (MMF) reduces blood pressure in the deoxycorticosterone acetate (DOCA-) salt model. However, the mechanisms by which MMF prevent hypertension in the DOCA-salt model remain unclear. Recent studies indicate that immunosuppression can inhibit sodium transporter activity in the kidney, but its effect on vascular tone is not well characterized. Therefore, the aim of the present study was to analyze the vascular and renal tubular effects of MMF in the DOCA-salt model in rats (4 weeks without uninephrectomy). Co-treatment with MMF attenuated the rise in blood pressure from day 11 onward resulting in a significantly lower telemetric mean arterial pressure after 4 weeks of treatment (108 +/- 7 vs. 130 +/- 9 mmHg, P < 0.001 by two-way analysis of variance). MMF significantly reduced the number of CD3(+) cells in kidney cortex and inner medulla, but not in outer medulla. In addition, MMF significantly reduced urinary interferon-gamma excretion. Vascular tone was studied ex vivo using wire myographs. An angiotensin II type 2 {AT(2)) receptor antagonist blocked the effects of angiotensin II (Ang II) only in the vehicle group. Conversely, L-NAME significantly increased the Mg II response only in the MMF group. An endothelin A receptor blocker prevented vasoconstriction by endothelin-1 in the MMF but not in the vehicle group. MMF did not reduce the abundances of the kidney sodium transporters NHE3, NKCC2, NCC, or ENaC. Together, our ex vivo results suggest that DOCA-salt induces AT(2) receptor-mediated vasoconstriction. MMF prevents this response and increases nitric oxide availability. These data provide insight in the antihypertensive mechanism of MMF and the role of inflammation in dysregulating vascular tone.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] THE ROLE OF CALMODULIN IN NEUROTRANSMITTER RELEASE AND VASCULAR RESPONSIVENESS IN DOCA-SALT HYPERTENSION
    TSUDA, K
    NISHIO, I
    MASUYAMA, Y
    JOURNAL OF HYPERTENSION, 1986, 4 : S57 - S59
  • [22] Triptolide attenuates renal damage by limiting inflammatory responses in DOCA-salt hypertension
    Zhang, Jing
    Zhu, Mingjun
    Zhang, Shiyu
    Xie, Shiyang
    Gao, Yuan
    Wang, Youping
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 89
  • [23] EFFECTS OF K+-CANRENOATE ON THE DEVELOPMENT OF DOCA-SALT HYPERTENSION
    VARGAS, F
    HARO, JM
    JODAR, E
    SOLER, A
    DELRIO, CG
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1989, 41 (05) : 335 - 338
  • [24] Etoricoxib Attenuates Effect of Antihypertensives in a Rodent Model of DOCA-Salt Induced Hypertension
    Chugh, Preeta Kaur
    Gupta, Monica
    Agarwal, Monika
    Tekur, Uma
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2013, 35 (08) : 601 - 606
  • [25] Role of endothelin and vasopressin in DOCA-salt hypertension
    Yu, M
    Gopalakrishnan, V
    McNeill, JR
    BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (07) : 1447 - 1454
  • [26] ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension
    Callera, GE
    Touyz, RM
    Teixeira, SA
    Muscara, MN
    Carvalho, MHC
    Fortes, ZB
    Nigro, D
    Schiffrin, EL
    Tostes, RC
    HYPERTENSION, 2003, 42 (04) : 811 - 817
  • [27] COMPARISON OF THE VASCULAR AND GLOMERULAR CHANGES IN AORTIC-LIGATURE AND DOCA-SALT HYPERTENSION
    HEWITSON, T
    KAMITSUJI, H
    WHITWORTH, JA
    KINCAIDSMITH, P
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1989, 16 (08) : 641 - 645
  • [28] DEVELOPMENT OF DOCA-SALT HYPERTENSION IN THE BRATTLEBORO RAT
    SAITO, T
    YAJIMA, Y
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1982, 394 (OCT) : 309 - 318
  • [29] Sympathetic activation in the development of DOCA-salt hypertension
    Kandlikar, Sachin
    King, Andrew J.
    Novotny, Martin
    Fink, Gregory
    FASEB JOURNAL, 2008, 22
  • [30] EFLORNITHINE (DFMO) TREATMENT AND VASCULAR POLYAMINES IN ESTABLISHED HYPERTENSION IN THE DOCA-SALT RAT
    BROWN, M
    NEWMAN, P
    TROWBRIDGE, J
    ROSE, B
    PASS, S
    FEGER, A
    GUO, H
    OLSON, J
    SOLTIS, E
    FASEB JOURNAL, 1993, 7 (04): : A548 - A548